Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...

Shares of Hims & Hers Health Inc. ended Tuesday over 5% higher, lifting retail investor mood after the telehealth company ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Shares of Hims & Hers Health (NYSE: HIMS) surged on Tuesday, closing the session up 5.25% after having been up by as much as ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.5% in the afternoon session after the company revealed it will offer Eli Lilly's weight-loss medications (Zepbound) on its ...

Hims & Hers Health said it is expanding its weight-loss offerings with the addition of Eli Lilly & Co.'s Zepbound and generic liraglutide. The telehealth-consultation platform on Tuesday said it aimed ...

Joelle Pineau said she would step down effective May 30, creating an executive vacancy as the company aggressively invests and competes in the booming sector. Visa, Amex and Mastercard are all ...

Assessing whether Trump's recent aggressive tariff talk is all bluster, no muster kept stocks volatile on Tues. S&P 500 ...

EDT Hims & Hers to sell Zepbound through telehealth platform, Bloomberg reportsDon't Miss Our End of Quarter Offers: Discover the ...